Bone Tax Provision vs Ebitda Analysis
| BBLG Stock | USD 1.31 0.06 4.80% |
Bone Biologics financial indicator trend analysis is way more than just evaluating Bone Biologics Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bone Biologics Corp is a good investment. Please check the relationship between Bone Biologics Tax Provision and its Ebitda accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Tax Provision vs Ebitda
Tax Provision vs Ebitda Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bone Biologics Corp Tax Provision account and Ebitda. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Bone Biologics' Tax Provision and Ebitda is -0.01. Overlapping area represents the amount of variation of Tax Provision that can explain the historical movement of Ebitda in the same time period over historical financial statements of Bone Biologics Corp, assuming nothing else is changed. The correlation between historical values of Bone Biologics' Tax Provision and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Tax Provision of Bone Biologics Corp are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Tax Provision i.e., Bone Biologics' Tax Provision and Ebitda go up and down completely randomly.
Correlation Coefficient | -0.01 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Ebitda
Most indicators from Bone Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. The current Selling General Administrative is estimated to decrease to about 2 M. The current Tax Provision is estimated to decrease to 2,133
Bone Biologics fundamental ratios Correlations
Click cells to compare fundamentals
Bone Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bone Biologics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Common Stock Shares Outstanding | 12.2K | 51.1K | 43.1K | 47.6K | 263.1K | 250.0K | |
| Total Assets | 30.8K | 0.0 | 6.7M | 8.5M | 3.7M | 2.3M | |
| Net Debt | 11.3M | 11.7M | (6.7M) | (7.5M) | (3.0M) | (2.9M) | |
| Cash | 24.1K | 0.0 | 6.7M | 7.5M | 3.0M | 2.0M | |
| Cash And Short Term Investments | 955.4K | 24.1K | 6.7M | 7.5M | 3.0M | 2.1M | |
| Liabilities And Stockholders Equity | 1.0M | 30.8K | 6.7M | 8.5M | 3.7M | 2.5M | |
| Total Current Assets | 30.8K | 0.0 | 6.7M | 8.5M | 3.7M | 2.3M | |
| Other Current Liab | 513.7K | 535.6K | 1.5M | 2.5M | 470.7K | 447.2K | |
| Total Current Liabilities | 578.4K | 13.7M | 99.9K | 2.5M | 831.4K | 789.8K | |
| Total Stockholder Equity | (11.9M) | (13.7M) | 6.6M | 5.9M | 2.9M | 3.1M | |
| Retained Earnings | (67.0M) | (68.9M) | (70.5M) | (72.0M) | (80.9M) | (76.9M) | |
| Other Stockholder Equity | 55.1M | 55.2M | 77.0M | 77.9M | 83.8M | 47.8M | |
| Total Liab | 11.9M | 13.7M | 99.9K | 2.5M | 831.4K | 789.8K | |
| Short Long Term Debt Total | 8.2M | 9M | 11.3M | 11.7M | 13.5M | 8.3M | |
| Other Current Assets | 105.2K | 85.3K | 6.7K | 956.9K | 711.2K | 746.8K | |
| Net Tangible Assets | (8.6M) | (11.9M) | (13.7M) | 6.6M | 7.6M | 7.9M | |
| Accounts Payable | 42.9K | 465.4K | 99.9K | 888.46 | 360.7K | 202.9K | |
| Non Current Liabilities Total | 11.3M | 12.2M | 99.9K | 888.46 | 799.61 | 759.63 | |
| Net Invested Capital | (547.6K) | (2.0M) | 6.6M | 5.9M | 2.9M | 2.1M | |
| Net Working Capital | (547.6K) | (13.7M) | 6.6M | 5.9M | 2.9M | 3.1M |
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.57) | Return On Equity (1.19) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.